Roche to present data from 15 medicines across its portfolio of cancer immunotherapy and targeted medicines during the 2015 European Cancer Congress
"With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer," said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. "At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancers."
In addition to data for alectinib, atezolizumab and cobimetinib, results will be presented across multiple tumour types from Roche’s cancer immunotherapy and targeted medicines pipeline including CEA-IL2v (RG7813), IDO Inhibitor (GDC-0919) and vanucizumab (anti-Ang2/VEGF, RG7221). The table below contains key abstracts featuring Roche medicines, including late breaking abstracts that will be presented during the Congress.
Follow Roche on Twitter via @Roche and keep up to date with the 2015 European Cancer Congress news and updates by using the hashtag #ECC2015.
Overview of key abstracts featuring Roche medicines
| Medicine | Abstract title | Abstract number |
|---|---|---|
atezolizumab (MPDL3280A; anti-PDL1) (investigational) | POPLAR: Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). J. Vansteenkiste et al. | #14LBA (Proffered Paper Session) Sunday September 27 09:15 CET |
| BIRCH: Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected non-small cell lung cancer (NSCLC). Benjamin Besse et al. | #16LBA (Proffered Paper Session) Sunday September 27 | |
| IMvigor210: Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). J. Rosenberg et al. | #21LBA (Proffered Paper Session) Sunday September 27 10:40 CET | |
| Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. G. Giaccone et al. | #513 (Poster Session) Saturday September 26 16:45 CET | |
| NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents distinct cancer subtypes. P. Schmid et al. | #3017 (Poster Discussion) Sunday September 27 08:00 CET | |
| alectinib | Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). F. Barlesi et al. | #3101 (Poster Session) Sunday 27 September 09:15 CET |
| cobimetinib (Cotellic) | Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. G. McArthur et al. | #25LBA (Proffered Paper Session) Sunday 27 September 12:10 CET |
CEA-IL2v (RG7813) (investigational) | Clinical evidence of intra-tumoral immune activation and tumor targeting with RG7813, a CEA-targeted engineered IL-2 immunocytokine. J. Tabernero et al. | #505 (Proffered Paper Session) Sunday 27 September 18:30 CET |
IDO Inhibitor (GDC-0919) (investigational) | Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. A. Nayak et al. | #346 (Poster Session) Sunday 27 September 16:45 CET |
vanucizumab (anti-Ang2/VEGF, RG7221) (investigational) | Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. T. Nayak et al. | #304 (Proffered Paper Session) Saturday 26 September 11:35 CET |
About Roche in personalised cancer immunotherapy
For more than 30 years, Roche has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalised cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Roche is studying more than 20 investigational medicines, seven of which are in clinical trials. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Комментарии